General Information of Drug (ID: DM5PTB9)

Drug Name
4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol Drug Info
Synonyms CHEMBL172912; 4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol; SCHEMBL7212305
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
15516780
TTD Drug ID
DM5PTB9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [2]
Apratastat DM8W4N9 Rheumatoid arthritis FA20 Phase 2 [3]
PMID17935984C1 DMO1IHL Pain MG30-MG3Z Clinical trial [4]
PMID29130358-Compound-Figure18(14a) DMHIBTZ N. A. N. A. Patented [5]
PMID29130358-Compound-Figure16(9b) DMPAQLZ N. A. N. A. Patented [5]
PMID29130358-Compound-Figure16(9a) DMKX5R8 N. A. N. A. Patented [5]
PMID29130358-Compound-Figure18(14) DM7WXJ9 N. A. N. A. Patented [5]
PMID29130358-Compound-Figure16(9c) DM0ZRI9 N. A. N. A. Patented [5]
GM6001 DM7V9CT Corneal ulcer 9A76 Discontinued in Phase 2 [6]
RS-130830 DMOTANY Hepatitis C virus infection 1E51.1 Discontinued in Phase 2 [7]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prinomastat DM9HOKG Lung cancer 2C25.0 Approved [8]
Marimastat DM6V34C Pancreatic cancer 2C10 Phase 3 [9]
CIPEMASTAT DM803GL Rheumatoid arthritis FA20 Phase 3 [10]
Apratastat DM8W4N9 Rheumatoid arthritis FA20 Phase 2 [3]
PMID29130358-Compound-Figure18(14a) DMHIBTZ N. A. N. A. Patented [5]
PMID29130358-Compound-Figure10(2a) DMFWXPS N. A. N. A. Patented [5]
BMS 275291 DMKSFPE Kaposi sarcoma 2B57 Discontinued in Phase 3 [11]
GM6001 DM7V9CT Corneal ulcer 9A76 Discontinued in Phase 2 [12]
RS-130830 DMOTANY Hepatitis C virus infection 1E51.1 Discontinued in Phase 2 [7]
XL784 DMICR39 Diabetic nephropathy GB61.Z Discontinued in Phase 2 [13]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Matrix metalloproteinase-1 (MMP-1) TTMX39J MMP1_HUMAN Inhibitor [1]
Matrix metalloproteinase-13 (MMP-13) TTHY57M MMP13_HUMAN Inhibitor [1]

References

1 Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.
2 High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005.
3 Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9.
4 Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6529-34.
5 Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
6 Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia si... J Biol Chem. 2007 Sep 21;282(38):27781-91.
7 Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.
8 AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45.
9 Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81.
10 Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014 Apr;82(4):1710-8.
11 Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1;112(5):1083-8.
12 Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with i... Bioorg Med Chem. 2008 Sep 15;16(18):8745-59.
13 Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.